Mega-Brands: Investing in Mega Trends & the Mega Brands Best Positioned to Add Value to Your Wallet

S4 - Ep 14: Lilly & Obesity Disruption


Listen Later

Eli Lilly has been a monster stock over the last 5 years. It's compounded at 40%+ a year versus the market at roughly 11%. This great biopharma brand spends $6B a year on R&D, organically grows well, grows the dividend 15% a year and has a full pipeline thats diverse. This management team is second to none. The stock is not cheap anymore and it's a bit crowded but long-term we see great things for this brand. Mounjaro and Tirzepatide get alll the attention given their blockbuster potential but this company does $33B in annual revenue and very little is coming from the obesity and chronic over-weightedness theme thus far. In this quick video, I update people on what we see and why we still like the name long term.


For more information on investing in dominant, innovative growth brands:

https://www.globalbrandsmatter.com/dynamic-portfolio

...more
View all episodesView all episodes
Download on the App Store

Mega-Brands: Investing in Mega Trends & the Mega Brands Best Positioned to Add Value to Your WalletBy Eric Clark


More shows like Mega-Brands: Investing in Mega Trends & the Mega Brands Best Positioned to Add Value to Your Wallet

View all
Animal Spirits Podcast by The Compound

Animal Spirits Podcast

1,998 Listeners

The Compound and Friends by The Compound

The Compound and Friends

2,052 Listeners

All-In with Chamath, Jason, Sacks & Friedberg by All-In Podcast, LLC

All-In with Chamath, Jason, Sacks & Friedberg

9,207 Listeners

Call Me Back - with Dan Senor by Ark Media

Call Me Back - with Dan Senor

3,155 Listeners

Business Breakdowns by Colossus | Investing & Business Podcasts

Business Breakdowns

353 Listeners

Long Term Investing - With Baskin Wealth Management by Barry Schwartz

Long Term Investing - With Baskin Wealth Management

7 Listeners